Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibritumomab tiuxetan plus rituximab as initial therapy for patients with high tumor burden, indolent histology non-Hodgkin's lymphoma.

Trial Profile

Ibritumomab tiuxetan plus rituximab as initial therapy for patients with high tumor burden, indolent histology non-Hodgkin's lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab (Primary)
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Jun 2018 Status changed from completed to discontinued.
    • 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Dec 2011 Planned Eed date changed from 1 Dec 2011 to 1 Feb 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top